About usLearn more about Imperagen and meet our team

About us

Learn more about Imperagen and meet our team

Founded by a team of enzyme engineers and computational biologists as a spin-out of The University of Manchester, we are increasing the speed and reliability of enzyme engineering to unlock the full potential of enzyme technology.

Based in the heart of Manchester, UK, the historic centre of the world’s first industrial revolution and a hub of computing innovation, Imperagen will be at the forefront of the next bio-revolution.

Meet our team

Management Team / Executive Board Members

Andrew Currin

Chief Scientific Officer – Co-founder

Andrew is a leading expert in the fields of directed evolution, enzymology, and synthetic biology. Andrew’s driving interest is accelerating protein engineering through advancing techniques in gene assembly and laboratory automation. He has developed multiple novel DNA assembly approaches that provide the technology foundations for Imperagen’s fully automated enzyme engineering platform. 

He has also authored numerous papers and edited books on enzyme engineering and is a named inventor on several patents. He has a PhD in Biochemistry from The University of Manchester.

Andrew Almond

Chief Executive Officer – Co-founder

Andrew is a serial entrepreneur with a strong track record in successful commercialisation of biotechnology. He co-founded C4X Discovery, a drug discovery company, and led the company as CEO to a successful series-A fundraise, before stepping back to CTO and helping to deliver a successful IPO in 2014. 

Andrew also has over 20 years of experience in managing R&D projects, both within a university and a commercial environment. These projects place a particular emphasis on using computers to understand complex biochemical problems, which lie at the centre of Imperagen’s AI-based technology. He currently holds a part-time Readership in Physical Chemistry at The University of Manchester.

Tim Eyes

Chief Product Officer – Co-founder

As CPO, Tim drives product development and commercial engagement for Imperagen. An experienced protein engineer, his scientific career started in antibody technology and biotherapeutics for Big Pharma. More recently he has pivoted his interests towards the vast potential and importance of enzyme technology in sustainable biomanufacturing. 

This has led Tim to co-develop the founding technology of Imperagen and help build its early commercial strategy. He has a PhD in Biotechnology and held an Enterprise Fellowship at The University of Manchester. He has authored several scientific papers and is a named inventor for a novel enzyme-based process for API synthesis.

Non-Executive Board Members

Peter Seufer-Wasserthal

Non-Executive Chairman

Peter brings over 30 years of industrial biotechnology and life sciences commercialisation experience, supporting biotechnology companies’ development and profitability.

Mark Wyatt

Director – Investment Director Northern Gritstone

Alex Wilson

Director – Partner IQ Capital

Advisory Board

John Woodley

Advisor, Biocatalysis

John is currently Professor of Chemical Engineering at Technical University of Denmark. He has published over 300 papers with over 30 years’ experience in the scale-up and scale-down of biocatalytic processes.

Frank Craig

Advisor, Platform Technology and Automation

Frank was a co-founder and a VP of Aurora Biosciences (San Diego, USA) and has also worked for GSK and GE Healthcare in senior scientific roles. Frank has raised over £250m in investment and commercial partnerships.

Mark Roberts

Advisor, Business Development

Mark has over 30 years industrial experience with strong technical expertise in a wide range of process technologies.  He transitioned to commercial roles building relationships in the areas of automation, digitalisation, and AI.

Copyright 2024 ® Imperagen - All rights reserved - Company no. 13761050 - Williams House, Lloyd Street North, Manchester Science Park, Manchester, England, M15 6SE